NCT04768400View on ClinicalTrials.gov

MEP and Neuromuscular Blocker

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 9, 2021

Primary Completion Date

May 13, 2022

Study Completion Date

May 13, 2022

Conditions
Brain Tumor
Interventions
DRUG

Arm I (MEP)

Arm I (MEP): Motor evoked potential will be measured in various degree of the neuromuscular blockade.

Trial Locations (1)

Unknown

GangnamSeverance Hospital, Seoul

All Listed Sponsors
lead

Gangnam Severance Hospital

OTHER

NCT04768400 - MEP and Neuromuscular Blocker | Biotech Hunter | Biotech Hunter